{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:57:21Z","timestamp":1790204241564,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>With the recent approval of anti-\u03b2-amyloid (A\u03b2) treatment for Alzheimer\u2019s disease (AD), a demand has emerged for scalable, convenient and accurate estimations of brain A\u03b2 burden for the detection of AD that would enable timely, accurate and reliable diagnosis in one\u2019s primary care physician\u2019s (PCPs) office as called for recently by World Health Organization (WHO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>MemTrax, a 2-minute online memory test, was selected as the digital biomarker of cognitive impairment, and blood-based biomarkers (BBMs) including A\u03b242, A\u03b240, P-tau181, GFAP and NfL were used to estimate AD-related metrics in different groups of elderly individuals (<jats:italic>n<\/jats:italic>\u2009=\u2009349) for comparison with A\u03b2 PET scans of brain A\u03b2 burden. The correlations between MemTrax, MoCA, BBMs and brain A\u03b2 burden, expressed in centiloid (CL) values, were analyzed for predicting CL value alone or in combinations using machine-learning (ML).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Both MemTrax and the MoCA were able to differentiate A\u03b2 status similarly. Integration of MemTrax and BBMs using ML, however, significantly improved the AUCs (over the same with MoCA) for differentiating A\u03b2 status. MemTrax and p-Tau181\/A\u03b242 composite showed the strongest relationship with CL value among other BBMs. Most importantly, regression analyses of MemTrax and p-Tau181\/A\u03b242 aptly predicted CL values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The combination of MemTrax and BBMs provides an accurate, convenient, non-invasive, cost-effective and scalable way to estimate A\u03b2 load, which provides an opportunity for mass screening and timely and accurate diagnosis of AD. Our findings could also facilitate more effective AD clinical management in the PCPs office worldwide for more equitable access to current standard of care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01801-y","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T05:29:02Z","timestamp":1751693342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predicting brain amyloid load with digital and blood-based biomarkers"],"prefix":"10.1186","volume":"17","author":[{"given":"Weineng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis B.","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wesson","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"1801_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2174\/1567205018666211207094630","volume":"18","author":"F Bature","year":"2021","unstructured":"Bature F, Pappas Y, Pang D, Guinn BA. Can Non-invasive biomarkers lead to an earlier diagnosis of alzheimer\u2019s disease?? Curr Alzheimer Res. 2021;18:908\u201313.","journal-title":"Curr Alzheimer Res"},{"key":"1801_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/agm2.12069","volume":"2","author":"X Zhou","year":"2019","unstructured":"Zhou X, Ashford JW. Advances in screening instruments for alzheimer\u2019s disease. Aging Med (Milton). 2019;2:88\u201393.","journal-title":"Aging Med (Milton)"},{"key":"1801_CR3","doi-asserted-by":"crossref","unstructured":"Dhillon S, Aducanumab. First Approval Drugs. 2021;81:1437\u201343.","DOI":"10.1007\/s40265-021-01569-z"},{"key":"1801_CR4","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","DOI":"10.1056\/NEJMoa2212948"},{"key":"1801_CR5","doi-asserted-by":"crossref","unstructured":"Chin NA, Erickson CM. Alzheimer\u2019s disease, biomarkers, and mAbs - What does primary care need?? N Engl J Med. 2024;390:2229\u201331.","DOI":"10.1056\/NEJMp2401854"},{"key":"1801_CR6","doi-asserted-by":"crossref","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early alzheimer\u2019s disease using combinations of plasma Abeta42\/Abeta40 and p-tau. Alzheimers Dement. 2022;18:283\u201393.","DOI":"10.1002\/alz.12395"},{"key":"1801_CR7","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma biomarker strategy for selecting patients with alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 2024;81:69\u201378.","DOI":"10.1001\/jamaneurol.2023.4596"},{"key":"1801_CR8","doi-asserted-by":"crossref","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dore V, et al. Plasma Abeta42\/40 ratio, p-tau181, GFAP, and NfL across the alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19:1117\u201334.","DOI":"10.1002\/alz.12724"},{"key":"1801_CR9","doi-asserted-by":"crossref","unstructured":"Arnold SE, Louneva N, Cao K, Wang LS, Han LY, Wolk DA, et al. Cellular, synaptic, and biochemical features of resilient cognition in alzheimer\u2019s disease. Neurobiol Aging. 2013;34:157\u201368.","DOI":"10.1016\/j.neurobiolaging.2012.03.004"},{"key":"1801_CR10","doi-asserted-by":"crossref","unstructured":"Pan F, Huang Y, Cai X, Wang Y, Guan Y, Deng J, et al. Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain beta-amyloid pathology. Commun Med (Lond). 2023;3:65.","DOI":"10.1038\/s43856-023-00295-9"},{"key":"1801_CR11","doi-asserted-by":"crossref","unstructured":"van der Hoek MD, Nieuwenhuizen A, Keijer J, Ashford JW. The memtrax test compared to the Montreal cognitive assessment Estimation of mild cognitive impairment. J Alzheimers Dis. 2019;67:1045\u201354.","DOI":"10.3233\/JAD-181003"},{"key":"1801_CR12","doi-asserted-by":"crossref","unstructured":"Liu X, Chen X, Zhou X, Shang Y, Xu F, Zhang J, et al. Validity of the memtrax memory test compared to the Montreal cognitive assessment in the detection of mild cognitive impairment and dementia due to alzheimer\u2019s disease in a Chinese cohort. J Alzheimers Dis. 2021;80:1257\u201367.","DOI":"10.3233\/JAD-200936"},{"key":"1801_CR13","doi-asserted-by":"crossref","unstructured":"Ashford JW, Tarpin-Bernard F, Ashford CB, Ashford MT. A computerized Continuous-Recognition task for measurement of episodic memory. J Alzheimers Dis. 2019;69:385\u201399.","DOI":"10.3233\/JAD-190167"},{"key":"1801_CR14","doi-asserted-by":"crossref","unstructured":"Ashford JW, Gere E, Bayley PJ. Measuring memory in large group settings using a continuous recognition test. J Alzheimers Dis. 2011;27:885\u201395.","DOI":"10.3233\/JAD-2011-110950"},{"key":"1801_CR15","doi-asserted-by":"crossref","unstructured":"Liu W, Yu L, Deng Q, Li Y, Lu P, Yang J, et al. Toward digitally screening and profiling AD: A GAMLSS approach of memtrax in China. Alzheimers Dement. 2024;20:399\u2013409.","DOI":"10.1002\/alz.13430"},{"key":"1801_CR16","doi-asserted-by":"crossref","unstructured":"Chen W, Lin C, Su F, Fang Y, Liu G, Chen YC, et al. Early diagnosis of mild cognitive impairment due to alzheimer\u2019s disease using a composite of memtrax and blood biomarkers. J Alzheimers Dis. 2023;94:1093\u2013103.","DOI":"10.3233\/JAD-230182"},{"key":"1801_CR17","doi-asserted-by":"crossref","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","DOI":"10.1111\/j.1365-2796.2004.01388.x"},{"key":"1801_CR18","doi-asserted-by":"crossref","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"1801_CR19","doi-asserted-by":"crossref","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887\u201394.","DOI":"10.2967\/jnumed.109.065284"},{"key":"1801_CR20","doi-asserted-by":"crossref","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with Florbetapir standardized uptake value ratios to the centiloid scale. Alzheimers Dement. 2018;14:1565\u201371.","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"1801_CR21","doi-asserted-by":"crossref","unstructured":"Amadoru S, Dore V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in centiloid units with neuropathological findings in alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22.","DOI":"10.1186\/s13195-020-00587-5"},{"key":"1801_CR22","doi-asserted-by":"crossref","unstructured":"Mila-Aloma M, Shekari M, Salvado G, Gispert JD, Arenaza-Urquijo EM, Operto G, et al. Cognitively unimpaired individuals with a low burden of Abeta pathology have a distinct CSF biomarker profile. Alzheimers Res Ther. 2021;13:134.","DOI":"10.1186\/s13195-021-00863-y"},{"key":"1801_CR23","doi-asserted-by":"crossref","unstructured":"Salvado G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suarez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27.","DOI":"10.1186\/s13195-019-0478-z"},{"key":"1801_CR24","doi-asserted-by":"crossref","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","DOI":"10.1186\/1471-2105-12-77"},{"key":"1801_CR25","doi-asserted-by":"crossref","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suarez-Calvet M et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024.","DOI":"10.1038\/s41582-024-00977-5"},{"key":"1801_CR26","unstructured":"Administration UFaD. FDA permits marketing for new test to improve diagnosis of Alzheimer\u2019s disease. 2022."},{"key":"1801_CR27","doi-asserted-by":"crossref","unstructured":"Figdore DJ, Wiste HJ, Bornhorst JA, Bateman RJ, Li Y, Graff-Radford J, et al. Performance of the lumipulse plasma Abeta42\/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimers Dement (Amst). 2024;16:e12545.","DOI":"10.1002\/dad2.12545"},{"key":"1801_CR28","doi-asserted-by":"crossref","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024.","DOI":"10.1002\/alz.13859"},{"key":"1801_CR29","doi-asserted-by":"crossref","unstructured":"Tsoy E, La Joie R, VandeVrede L, Rojas JC, Yballa C, Chan B, et al. Scalable plasma and digital cognitive markers for diagnosis and prognosis of alzheimer\u2019s disease and related dementias. Alzheimers Dement. 2024;20:2089\u2013101.","DOI":"10.1002\/alz.13686"},{"key":"1801_CR30","doi-asserted-by":"crossref","unstructured":"Papp KV, Samaroo A, Chou HC, Buckley R, Schneider OR, Hsieh S, et al. Unsupervised mobile cognitive testing for use in preclinical alzheimer\u2019s disease. Alzheimers Dement (Amst). 2021;13:e12243.","DOI":"10.1002\/dad2.12243"},{"key":"1801_CR31","doi-asserted-by":"crossref","unstructured":"Sanabria A, Alegret M, Rodriguez-Gomez O, Valero S, Sotolongo-Grau O, Monte-Rubio G, et al. The Spanish version of Face-Name associative memory exam (S-FNAME) performance is related to amyloid burden in subjective cognitive decline. Sci Rep. 2018;8:3828.","DOI":"10.1038\/s41598-018-21644-y"},{"key":"1801_CR32","doi-asserted-by":"crossref","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","DOI":"10.1056\/NEJMoa2100708"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01801-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T05:29:10Z","timestamp":1751693350000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1801"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01801-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the Helsinki declaration of 1975 and was approved by the ethical committee of the first Affiliated Hospital of Sun Yat-sen University in Guangzhou, Guangdong, China. All participants or guardians voluntarily signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Ashford developed the MemTrax test and consults with his son, Curtis B. Ashford, to market MemTrax commercially. Dr. Zhou worked with Dr. Ashford and Curtis Ashford at MemTrax LLC to develop and implement MemTrax in China, which is marketed commercially by SJN Biomed, where Dr. Zhou was once an executive director. The other authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}